Halozyme Therapeutics (HALO) Says AbbVie (ABBV) Discontinued Development Using Halozyme ENHANZE
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that AbbVie (NYSE: ABBV) has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of a phase 1 study in which the target results were not achieved.
Halozyme and AbbVie will continue to work collaboratively to identify additional targets for co-development under their 2015 Global Collaboration and Licensing agreement. TNF-alpha was the first nominated target of nine included as part of the agreement.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme Therapeutics (HALO): Top Pick Under A Trump Presidency - Piper Jaffray
- Stocks with increasing call volume on January 23
- Stocks with Implied Volatility Movement
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!